Day 1 | Day 2 | Download Brochure | Delegate List
Wednesday, April 28
7:45 am Continental Breakfast Break-Out Discussions:
The Challenge of MRSA
Moderator: Thomas D. Gootz, Ph.D., Thomas Gootz Consulting
Outer Membrane Biogenesis: A Neglected Drug Target in Gram-Negative Bacteria?
Moderator: Herbert P. Schweizer, Ph.D., Professor, FAAM, Associate Department Head, Associate Director, RMRCE, Dept. Microbiology, Immunology and Pathology, Colorado State University
8:55 Chairperson's Opening Remarks
Malcolm Page, Professor; Head of Biology, Research, Basilea Pharmaceutica International
9:00 Mutant Prevention Concentration (MPC) Testing for Predicting Resistance Prevention/Selection by Antimicrobial Agents
Joseph Blondeau, Ph.D., Head, Clinical Microbiology, Royal University Hospital and University of Saskatchewan
MPC defines the antimicrobial drug concentration required to block the growth of the least susceptible cell present in high density bacterial populations - such as those seen in human/animal infections. Such testing when considered with PK/PD modelling may provide insight on the likelyhood of resistance selection/prevention by antimicrobial agents. MPC testing involves an inocula of >= 1 billion organisms as compared to MIC testing utilizing 100,000 CFU/ml. MPC testing may more accurately reflect bacterial population susceptibility.
9:30 NVC-422, a Novel N-Chlorotaurine Derivative as Topical Antimicrobial
Dmitri Debabov, Ph.D., Assistant Director, Micro and Cell Biology, NovaBay Pharmaceuticals
N,N-dichloro-2,2-dimethyltaurine (NVC-422) is a broad spectrum, fast acting non-antibiotic antimicrobial with activity against Gram-negative and Gram-positive bacteria, bacterial biofilms, yeast and viruses. There is low frequency of spontaneous resistance and low potential for cross-resistance of NVC-422 with antibiotics and antiseptics. NVC-422 retains rapid activity in the presence of human serum, plasma and serum albumin. It has prolonged postantibiotic effect. At the present time, NVC-422 is in human efficacy study for eye and skin infection.
10:00 Sponsored Presentation I (Opportunity Available)
10:15 Coffee Break, Poster and Exhibit Viewing
11:00 Artilysins – Novel Tools to Combat Antibiotic Resistant Bacteria
Stefan Miller, Ph.D., CEO, Lisando GmbH
Increasing antibiotic resistance of bacteria provides a clear need for novel ways to combat bacterial pathogens. ARTILYSINS, designed enzymes efficiently disrupt surfaces structures of gram negative and gram positive bacteria. This enzymatic mechanism enables even killing of highly antibiotic resistant Pseudomonas aeruginosa.
11:30 Dissecting Assembly of Multi-Component Drug Efflux Complexes
Helen I. Zgurskaya, Ph.D., Associate Professor of Chemistry and Biochemistry, University of Oklahoma
Multidrug efflux pumps are major contributors to intrinsic antibiotic resistance of Gram-negative pathogens. The basic structure of these pumps includes an inner membrane transporter, a periplasmic membrane fusion protein and an outer membrane channel. However, the architecture and composition of multidrug efflux complexes vary significantly because of the topological and functional diversity of the inner membrane transporters. This presentation is focused on our current efforts to understand the mechanism of assembly of multi-component drug efflux complexes.
12:00 pm End of Conference
Day 1 | Day 2